Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - feline calicivirus - inactivated; feline panleucopenia virus - inactivated; feline rhinotracheitis virus - inactivated; thiomersal - parenteral liquid/solution/suspension - feline calicivirus - inactivated vaccine-viral active 0.0 p; feline panleucopenia virus - inactivated vaccine-viral active 0.0 p; feline rhinotracheitis virus - inactivated vaccine-viral active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - cat | cat - queen | cat - tom | kitten - feline calicivirus | feline enteritis | feline rhinotracheitis | calicivirus (feline) | enteritis (feline) | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - infectious bovine rhinotraceitis virus - suspension for injection - inactivated viral vaccine - cattle

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - infectious bovine rhinotraceitis virus - emulsion for injection - inactivated viral vaccine - cattle

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - bovine herpes virus type 1 (bhv-1), strain difivac (ge-negative), modified live (attenuated) virus - lyophilisate and solvent for suspension for injection - . - bovine rhinotracheitis virus (ibr) - cattle - immunological - live vaccine

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - infectious bovine rhinotraceitis virus - suspension for injection - inactivated viral vaccine - cattle

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - feline panleucopenia; feline calicivirus; feline rhinotracheitis - misc. vaccines or anti sera - feline panleucopenia vaccine active 0.0 tci50/ml; feline calicivirus vaccine-viral active 0.0 tci50/ml; feline rhinotracheitis vaccine-viral active 0.0 tci50/ml - immunotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: aluminium; water for injections; borax; sodium chloride - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; aluminium; sodium chloride; water for injections - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; water for injections; sodium chloride; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: sodium chloride; borax; water for injections; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.